| Literature DB >> 22205349 |
M Wiśniewska-Ligier1, T Woźniakowska-Gęsicka, J Sobolewska-Dryjańska, A Markiewicz-Jóźwiak, M Wieczorek.
Abstract
Toxocariasis is a helminthozoonotic disease caused by ascarid larvae of Toxocara genus: Toxocara canis and Toxocara cati. In the reported study, the clinical course of toxocariasis and administered therapy were evaluated in 103 children. The majority of the children (68.9%) were from the rural environment, with a prevalence of boys (62.1%). At diagnosis of infection, 36 (35%) children reported recurrent abdominal pain, 19 (18.4%) headache, 6 (5.8%) loss of appetite, 2 subfebrile conditions, and 2 arthralgia, Moreover, 23 (22.3%) children demonstrated symptoms of atopic diseases; in 30 (29.1%) children, moderate enlargement of lymphatic nodes was noted. In five children (4.9%), ophthalmic examination revealed unilateral changes in the eye: in two cases retinitis; in one case fibrotic lesions in the vitreous body, complicated 1 year from diagnosis by retinal detachment; and in other children parafoveal lesions and cataract. Only two children with ocular changes at diagnosis reported visual disorders. In 64.3% of children, eosinophilia was observed. A covert form of the disease was diagnosed in 95.1% of the children and an ocular form in 4.9%. In all the children, antiparasitic treatment was implemented, repeated several times in some of them. After therapy, the mean titer of specific antibodies, the number of children with abdominal pains and enlarged lymphatic nodes were decreased, while headaches maintained at unchanged levels. In approximately one fourth of the children with negative results of antibodies after the therapy, the symptoms of the disease were still reported. Evaluation of the efficacy of treatment is not easy due to non-characteristic symptoms and low kinetics of specific anti Toxocara IgG decrease; however, high IgG titers suggest non-effective treatment of concomitant infection requiring subsequent therapy. Due to risk of ocular form, which may develop in any stage of the disease, irrespectively of specific antibodies concentrations, it seems justified to implement antiparasitic treatment in all children infected with T. canis.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22205349 PMCID: PMC3362726 DOI: 10.1007/s00436-011-2772-y
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289
Characteristic of the study group children in terms of age, sex, and place of residence
| Number of children ( | % of children | ||
|---|---|---|---|
| Age (years), medium±SD (min; max) | 7.3 ± 3.4 (1.4; 14.7) | ||
| Sex | Female | 39 | 37.9 |
| Male | 64 | 62.1 | |
| Place of residence | Town >200,000 population | 12 | 11.7 |
| Town <100,000 population | 20 | 19.4 | |
| Village | 71 | 68.9 |
An analysis of clinical symptoms in the analyzed group of children with toxocariasis
| Clinical symptoms | Number of children | % of children |
|---|---|---|
| Subfebrile conditions | 2 | 1.9 |
| Abdominal pain | 36 | 35 |
| Headache | 19 | 18.4 |
| Loss of appetite | 6 | 5.8 |
| Arthralgia | 2 | 1.9 |
| A history of allergic symptoms | 23 | 22.3 |
| Abdominal tenderness | 1/103 | 1 |
| Enlargement of lymphatic nodes | 30 | 29.1 |
| Cervical | 22 | |
| Submandibular | 6 | |
| Axillary | 6 | |
| Changes in the eye | 5 | 4.9 |
| Eosinophilia at infection diagnosis (studies available in 70 children) | 45 | 64.3 |
| Mild anemia | 1 | 1 |
An analysis of the number of antiparasitic treatments vs. the place of residence
| 1st treatment course | 2nd treatment course | 3rd treatment course | |
|---|---|---|---|
| Number of children (%) | Number of children (%) | Number of children (%) | |
| Children—inhabitants of towns with >200,000 population ( | 12 (100%) | 7 (58.3%) | 2 (16.7)* |
| Children—inhabitants of towns with <100,000 population ( | 20 (100%) | 16 (80%) | 8 (40%) |
| Children living in the village (N = 71) | 71 (100%) | 49 (69%) | 36 (50.7%)* |
*p < 0.05 (values differ significantly)
An analysis of the occurrence of selected clinical symptoms before and after particular antiparasitic treatment course
| Clinical symptoms | 1st treatment course (number of children) | 2nd treatment course (number of children) | 3rd treatment course (number of children) | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Before therapy | After therapy | Before therapy | After therapy | Before t therapy | After therapy | |
| Abdominal pain | 36 (35%) | 29 (29.1%) | 17 (23.6%) | 9 (12.5%) | 11 (23.9%)* | 4 (8.7%)* |
| Headache | 19 (18.4%) | 18 (18.4) | 9 (12.5%) | 6 (8.3%) | 4 (8.7%) | 1 (2.2%) |
| Loss of appetite | 6 (5.8%) | 4 (3.9%) | 5 (5.6%) | 3 (2.8%) | 2 (4.3%) | 3 (6.5%) |
| Enlargement of lymphatic nodes | 30 (29.1%)* | 18 (17.5%)* | 15 (20.8%) | 14 (19.4%) | 13 (28.3)* | 4 (8.7%)* |
*p < 0.05 (values differ statistically significant before and after treatment)
An analysis of selected clinical symptoms in children with a negative titer of antibodies against T. canis after treatment
| Clinical findings | 1st treatment course ( | 2nd treatment course ( | 3rd treatment course ( | |||
|---|---|---|---|---|---|---|
| Before therapy | After therapy | Before therapy | After therapy | Before therapy | After therapy | |
| Headache | 5 (26.3%) | 4 (21.1%) | 3 (27.3%) | 2 (18.2%) | 1 (16.7%) | 1 (16.7%) |
| Abdominal pain | 9 (47.4%) | 5 (26.3%) | 0 | 0 | 0 | 0 |
| Loss of appetite | 1 (5.3%) | 0 | 1 (9.1%) | 1 (9.1%) | 0 | 0 |
| Enlargement of lymphatic nodes | 8 (41.1%) | 3 (15.8%) | 4 (36.4%) | 1 (9.1%) | 1 (16.7%) | 0 |
An analysis of selected parameters in children with a negative titer of antibodies against T. canis after treatment
| Antibody titer before therapy (%) (medium ± SD) | Antibody titer after therapy (%) (medium ± SD) | The number of days from therapy onset to antibody titer assessment (medium ± SD) | The number of days from the 1st therapy to antibody titer assessment (medium ± SD) | Eosinophilia before therapy (medium ± SD) | Eosinophilia after therapy (medium ± SD) | |
|---|---|---|---|---|---|---|
| 1st therapy, | 70.2% ± 27 | <28 | 183 ± 110 | 183 ± 110 | 8.5 ± 5.7 | 4.8 ± 3.5 |
| 2nd therapy, | 73.1% ± 22.8 | <28 | 304.2 ± 211.8 | 527 ± 350.7 | 5.7 ± 1.9 | 5.5 ± 3.5 |
| 3rd therapy, | 69% ± 23.6 | <28 | 252.2 ± 141.5 | 719.8 ± 190.9 | 8 ± 6.9 | 5.2 ± 3 |
Correlations between the reduction of antibodies against T. canis after treatment and the level of antibodies before treatment in particular antiparasitic treatment courses
| Difference between antibody titers before and after the 1st treatment course | Difference between antibody titers before and after the 2nd treatment course | Difference between antibody titers before and after the 3rd treatment course | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Antibody titer before 1st therapy | 0.516 | 9.43E05 | – | – | – | – |
| Antibody titer before 2nd therapy | – | – | 0.47 | 0.003 | – | – |
| Antibody titer before 3rd therapy | – | – | – | – | 0.59 | 0.001 |
r Pearson’s correlation coefficient, p significance level
Correlations between eosinophil level reduction after treatment and eosinophil level before treatment in three consecutive antiparasitic treatments
| Difference between eosinophilia before and after the 1st treatment course | Difference between eosinophilia before and after the 2nd treatment course | Difference between eosinophilia before and after the 3rd treatment course | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Percentage of eosinophils before 1st therapy | 0.78 | 7.47E08 | – | – | – | – |
| Percentage of eosinophils before 2nd therapy | – | – | 0.53 | 0.005 | – | – |
| Percentage of eosinophils before 3 rd therapy | – | – | – | – | 0.64 | 0.006 |
r Pearson’s correlation coefficient, p significance level